Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,022,884
  • Shares Outstanding, K 180,442
  • Annual Sales, $ 13,453 M
  • Annual Income, $ 4,431 M
  • 60-Month Beta 1.08
  • Price/Sales 3.92
  • Price/Cash Flow 9.21
  • Price/Book 3.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 7.94
  • Number of Estimates 26
  • High Estimate 9.32
  • Low Estimate 6.47
  • Prior Year 6.99
  • Growth Rate Est. (year over year) +13.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
271.48 +8.24%
on 11/14/19
309.06 -4.92%
on 12/05/19
+2.45 (+0.84%)
since 11/12/19
3-Month
219.70 +33.75%
on 10/03/19
318.00 -7.59%
on 10/22/19
+61.54 (+26.49%)
since 09/12/19
52-Week
215.77 +36.18%
on 09/04/19
344.00 -14.58%
on 01/23/19
-28.76 (-8.91%)
since 12/12/18

Most Recent Stories

More News
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.

RHHBY : 38.4400 (-0.13%)
ABBV : 88.73 (+2.34%)
JNJ : 141.34 (+0.26%)
BIIB : 293.85 (+0.55%)
Biogen Up on New Data on Alzheimer's Candidate Aducanumab

Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.

NVS : 93.06 (+0.02%)
RHHBY : 38.4400 (-0.13%)
AMGN : 235.99 (+0.85%)
BIIB : 293.85 (+0.55%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (ACAD , BIIB , FLXN , DVAX , GBT )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ACAD : 44.52 (-1.09%)
BIIB : 293.85 (+0.55%)
FLXN : 20.82 (+0.14%)
Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.

AZN : 47.92 (-0.56%)
RHHBY : 38.4400 (-0.13%)
BIIB : 293.85 (+0.55%)
AUPH : 18.25 (-1.14%)
Biogen's Lupus Candidate Meets Endpoint in Phase II Study

Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.

AZN : 47.92 (-0.56%)
ANIK : 53.50 (-1.38%)
BIIB : 293.85 (+0.55%)
VRTX : 220.55 (+0.25%)
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

MRK : 89.57 (+0.66%)
SGEN : 112.26 (+0.83%)
CARA : 16.40 (+0.31%)
BIIB : 293.85 (+0.55%)
AXSM : 48.57 (+1.04%)
INCY : 92.85 (-2.19%)
Biogen's Shares Down on Rating Downgrade by Baird Analyst

Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.

NVS : 93.06 (+0.02%)
RHHBY : 38.4400 (-0.13%)
AMGN : 235.99 (+0.85%)
BIIB : 293.85 (+0.55%)
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)

- The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placebo

BIIB : 293.85 (+0.55%)
Watch for Biogen Inc to Potentially Rebound After Falling 1.28% Yesterday

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.16 to a high of $296.57. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $298.68...

BIIB : 293.85 (+0.55%)
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

Key highlights of the past week include regulatory and pipeline updates.

GBT : 76.89 (-1.99%)
ALXN : 112.47 (+2.71%)
ICPT : 115.93 (-2.87%)
BIIB : 293.85 (+0.55%)
AMGN : 235.99 (+0.85%)
CCXI : 33.28 (+6.63%)
CBAY : 1.72 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 298.89
1st Resistance Point 296.37
Last Price 293.85
1st Support Level 291.13
2nd Support Level 288.41

See More

52-Week High 344.00
Fibonacci 61.8% 295.02
Last Price 293.85
Fibonacci 50% 279.89
Fibonacci 38.2% 264.76
52-Week Low 215.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar